Acrivon Therapeutics, Inc. Common Stock - Asset Resilience Ratio
Acrivon Therapeutics, Inc. Common Stock (ACRV) has an Asset Resilience Ratio of 64.59% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Acrivon Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Acrivon Therapeutics, Inc. Common Stock to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Acrivon Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Acrivon Therapeutics, Inc. Common Stock.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $93.85 Million | 64.59% |
| Total Liquid Assets | $93.85 Million | 64.59% |
Asset Resilience Insights
- Very High Liquidity: Acrivon Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 64.59% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Acrivon Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Acrivon Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for Acrivon Therapeutics, Inc. Common Stock (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Acrivon Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 71.04% | $139.66 Million | $196.59 Million | +4.91pp |
| 2023-12-31 | 66.14% | $91.44 Million | $138.26 Million | +11.93pp |
| 2022-12-31 | 54.20% | $98.23 Million | $181.23 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $106.59 Million | -- |
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific propri… Read more